July 18, 2018 08:52 AM EDT
Financing
Deals
Pharma

By the num­bers: Se­ries A rounds are bust­ing out, plat­forms are in, M&A is down, val­u­a­tions surge and 2018 looks wicked big

John Carroll

Editor & Founder

Every 6 months we seem to get a new round of record num­bers for bio­phar­ma. And H1 is no ex­cep­tion.

Sil­i­con Val­ley Bank …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times